Daiichi Sankyo
As of the edition of 20 October 2026, Daiichi Sankyo runs 88 drugs, 18 of them marketed; it is on route A at 24 targets and on route B at 9 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 12 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 18 |
| Active | 17 |
| Went quiet | 26 |
| Stopped | 23 |
| Status not established | 4 |
| Total | 88 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Metformin | none listed | 4 |
| Ezetimibe | none listed | 3 |
| Denosumab | Ended 2022 (computed from the first US licence) | 1 |
| Minocycline | none listed | 0 |
| Trastuzumab deruxtecan | Ends 2031 (computed from the first US licence) | 3 |
| Vemurafenib | Ends 2030 (patent) | 1 |
| Edoxaban | Ends 2027 (patent) | 1 |
| Olmesartan medoxomil | none listed | 1 |
| Datopotamab deruxtecan | Ends 2037 (computed from the first US licence) | 2 |
| Colesevelam | none listed | 0 |
| Bempedoic acid | Ends 2040 (patent) | 3 |
| Quizartinib | Ends 2030 (exclusivity) | 3 |
| Pexidartinib | Ends 2036 (patent) | 0 |
| Nortriptyline | none listed | 1 |
| Ofloxacin | none listed | 0 |
| Taletrectinib | Ends 2033 (patent) | 8 |
| Troglitazone | none listed | 1 |
| Cefpodoxime proxetil | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 24 targets, route B at 9 targets.
All 33 rows on route A or B
In the product33 company-target rows on route A or B; 30 are not shown here, and no score is.
See all 33 targets where Daiichi Sankyo needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 137 trials led
- Heart and blood vessels: 59 trials led
- Lungs and airways: 38 trials led